{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:35:09Z","timestamp":1793432109829,"version":"4.5.0"},"reference-count":93,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Organ preservation for gastroesophageal junction (GEJ) and gastric cancers is emerging as an attainable\u2014but still selective\u2014therapeutic goal. The convergence of effective systemic therapy, enhanced imaging, and endoscopic sophistication has reframed the role of surgery from default to discretionary. Building on watch-and-wait experience from the rectal cancer paradigm (Organ Preservation for Rectal Adenocarcinoma trial and International Watch-and-Wait Database), readiness requires more than feasibility; it depends on biologic predictability, clinical reproducibility, and system capacity. This review synthesizes current evidence on when and for whom nonoperative management may achieve oncologic parity with resection. We examine biologic readiness, defined by tumor subsets such as microsatellite instability-high (MSI-H) and Epstein-Barr virus (EBV)\u2013positive cancers that display immune-mediated clearance after therapy; clinical readiness, reflected in trial data and surveillance protocols that safeguard against undertreatment; and system readiness, encompassing diagnostic infrastructure, workforce expertise, and equitable access to high-quality response evaluation. In esophageal\/GEJ disease, Surgery As Needed for Oesophageal cancer trial demonstrates that patients achieving a clinical complete response after chemoradiation can be managed with active surveillance and achieve survival noninferior to immediate surgery, with better early quality of life, provided programs use validated clinical response evaluation, protocolized surveillance, and rapid salvage capacity. For gastric cancer, organ preservation remains investigational outside biomarker-selected contexts (eg, MSI-H, EBV-positive). Implementation demands multidisciplinary infrastructure including validated response assessment, intensive surveillance protocols, and equitable access to biomarker testing and salvage surgery. Without these elements, organ preservation risks widening existing disparities. Across these domains, the evidence suggests a threshold of cautious readiness for GEJ primaries and emerging readiness for gastric cancer. The key challenge is not technical innovation but translation\u2014ensuring that the ability to preserve the organ does not outpace the ability to preserve outcomes. Progress toward that equilibrium will determine whether organ preservation becomes a universal standard or remains an institutional privilege.<\/jats:p>","DOI":"10.1200\/edbk-26-515500","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T20:59:29Z","timestamp":1767819569000},"source":"Crossref","is-referenced-by-count":3,"title":["Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Primetime?"],"prefix":"10.1200","volume":"46","author":[{"given":"Winta","family":"Mehtsun","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, UC San Diego School of Medicine, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola","family":"Van Doosselaere","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, UC San Diego School of Medicine, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1246-3235","authenticated-orcid":true,"given":"Ugwuji N.","family":"Maduekwe","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31020065"},{"key":"e_1_3_2_5_2","first-page":"544","article-title":"Systematic review on quality-of-life outcomes after gastrectomy for gastric carcinoma","volume":"6","author":"Shan B","year":"2015","unstructured":"Shan B, Shan L, Morris D, et al: Systematic review on quality-of-life outcomes after gastrectomy for gastric carcinoma. J Gastrointest Oncol 6:544-560, 2015","journal-title":"J Gastrointest Oncol"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e31828c4a19"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.4174\/astr.2022.103.1.19"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000838"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i42.6114"},{"key":"e_1_3_2_10_2","first-page":"619","article-title":"The change of bone mineral density and bone metabolism after gastrectomy for gastric cancer: A meta-analysis","volume":"31","author":"Xie WQ","year":"2020","unstructured":"Xie WQ, He M, Yu DJ, et al: The change of bone mineral density and bone metabolism after gastrectomy for gastric cancer: A meta-analysis. Osteoporos Int 31:619-632, 2020","journal-title":"Osteoporos Int"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2019.10.007"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04161-3"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.4836"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2409512"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11980-w"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0022"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.003"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00032"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01208"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50903"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31078-X"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30557-X"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30074-2"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-025-04984-w"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00027-0"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004930"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30201-8"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003397"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07638-8"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189294"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7692"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30531-9"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503701"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00975"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405195"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104134"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03614"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01136-7"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1529-x"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0275"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"e_1_3_2_47_2","first-page":"1124","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: The INFINITY study by GONO","volume":"35","author":"Pietrantonio F","year":"2024","unstructured":"Pietrantonio F, Raimondi A, Lonardi S, et al: Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: The INFINITY study by GONO. Ann Oncol 35:1124-1135, 2024","journal-title":"Ann Oncol"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2011.01.030"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2015.11.026"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2564-y"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000698"},{"key":"e_1_3_2_55_2","first-page":"948","article-title":"Global burden, risk factors, clinicopathological characteristics, molecular biomarkers and outcomes of microsatellite instability-high gastric cancer","volume":"16","author":"Zhang Z","year":"2024","unstructured":"Zhang Z, Huang J, Li Y, et al: Global burden, risk factors, clinicopathological characteristics, molecular biomarkers and outcomes of microsatellite instability-high gastric cancer. Aging 16:948-963, 2024","journal-title":"Aging"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.215"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00686"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02877-z"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1339757"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13090728"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01601"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2024.03.15"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2019.718"},{"key":"e_1_3_2_66_2","unstructured":"U.S. Food and Drug Administration: FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100589"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4034-1"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05274-w"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0093"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.22515"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2511566"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp175"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.01.18"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae093"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-15236-6"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-025-01353-1"},{"key":"e_1_3_2_80_2","first-page":"1500","article-title":"A decision support framework for genomically informed investigational cancer therapy","volume":"114","author":"Meric-Bernstam F","year":"2022","unstructured":"Meric-Bernstam F, Johnson A, Holla V, et al: A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 114:1500-1508, 2022","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259815"},{"key":"e_1_3_2_82_2","first-page":"1","article-title":"Navigating a path to equity in cancer care: The role of patient navigation","volume":"41","author":"Dixit N","year":"2021","unstructured":"Dixit N, Rugo HS, Burke NJ: Navigating a path to equity in cancer care: The role of patient navigation. Am Soc Clin Oncol Educ Book 41:1-8, 2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znad051"},{"key":"e_1_3_2_84_2","first-page":"350","article-title":"Impact of patient navigation on timely cancer care: The Patient Navigation Research Program","volume":"116","author":"Freund KM","year":"2024","unstructured":"Freund KM, Battaglia TA, Calhoun E, et al: Impact of patient navigation on timely cancer care: The Patient Navigation Research Program. J Natl Cancer Inst 116:350-359, 2024","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00630"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10576-z"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa003"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2507207"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2531-z"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14310-3"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30637-0"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2022.1038"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-018-1724-8"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81408-z"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-515500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:59:37Z","timestamp":1768510777000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-515500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1200\/EDBK-26-515500"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-515500","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"e515500"}}